(PATH) Uipath - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90364P1057
Stock:
Total Rating 23
Risk 47
Buy Signal -0.45
| Risk 5d forecast | |
|---|---|
| Volatility | 58.1% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.04 |
| Alpha | -37.58 |
| Character TTM | |
|---|---|
| Beta | 1.378 |
| Beta Downside | 0.225 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.58% |
| CAGR/Max DD | -0.17 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: PATH Uipath
UiPath, Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company delivers software robots that emulate human actions with precision and speed for organizations to automate repetitive tasks. Its platform's embedded AI, ML, and NLP capabilities improve decisioning and information processing; allows users to design and combine UI automations, API integrations, and AI-based document understanding in a single workflow; multi-tenant platform enterprise deployment with security and governance and Automation Cloud, which allows rapid automation without infrastructure overhead; and intuitive interface and low-code, drag-and-drop functionality. The company provides mining capabilities analyze the digital footprint of users' processes across all systems; tracks, measures, and forecasts automation performance, providing actionable metrics and predictive insights to continuously optimize business processes and maximize return on investment; and designed to enable people and automations to work together with each focusing on the processes to enhance productivity and improve business outcomes. It serves financial services, healthcare, manufacturing, retail, and public sector. The company was founded in 2005 and is headquartered in New York, New York.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 229.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.84 > 1.0 |
| NWC/Revenue: 78.43% < 20% (prev 104.9%; Δ -26.51% < -1%) |
| CFO/TA 0.12 > 3% & CFO 334.9m > Net Income 229.7m |
| Net Debt (-671.6m) to EBITDA (25.9m): -25.89 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (544.7m) vs 12m ago -3.24% < -2% |
| Gross Margin: 83.16% > 18% (prev 0.83%; Δ 8233 % > 0.5%) |
| Asset Turnover: 55.87% > 50% (prev 52.99%; Δ 2.88% > 0%) |
| Interest Coverage Ratio: -0.57 > 6 (EBITDA TTM 25.9m / Interest Expense TTM -40.1m) |
Altman Z'' -1.15
| A: 0.42 (Total Current Assets 2.01b - Total Current Liabilities 788.7m) / Total Assets 2.90b |
| B: -0.63 (Retained Earnings -1.81b / Total Assets 2.90b) |
| C: 0.01 (EBIT TTM 22.7m / Avg Total Assets 2.78b) |
| D: -1.83 (Book Value of Equity -1.78b / Total Liabilities 971.4m) |
| Altman-Z'' Score: -1.15 = CCC |
Beneish M -2.50
| DSRI: 1.01 (Receivables 496.1m/448.2m, Revenue 1.55b/1.41b) |
| GMI: 1.00 (GM 83.16% / 83.20%) |
| AQI: 1.83 (AQ_t 0.27 / AQ_t-1 0.15) |
| SGI: 1.10 (Revenue 1.55b / 1.41b) |
| TATA: -0.04 (NI 229.7m - CFO 334.9m) / TA 2.90b) |
| Beneish M-Score: -2.50 (Cap -4..+1) = BBB |
What is the price of PATH shares?
As of February 27, 2026, the stock is trading at USD 10.71 with a total of 51,489,933 shares traded.
Over the past week, the price has changed by -4.46%, over one month by -28.17%, over three months by -21.19% and over the past year by -15.87%.
Over the past week, the price has changed by -4.46%, over one month by -28.17%, over three months by -21.19% and over the past year by -15.87%.
Is PATH a buy, sell or hold?
Uipath has received a consensus analysts rating of 3.17.
Therefor, it is recommend to hold PATH.
- StrongBuy: 3
- Buy: 1
- Hold: 18
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the PATH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.9 | 48.7% |
| Analysts Target Price | 15.9 | 48.7% |
PATH Fundamental Data Overview February 26, 2026
P/E Trailing = 24.0476
P/E Forward = 16.8919
P/S = 3.4775
P/B = 4.0647
P/EG = 0.4825
Revenue TTM = 1.55b USD
EBIT TTM = 22.7m USD
EBITDA TTM = 25.9m USD
Long Term Debt = 82.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.59m USD (from shortTermDebt, last fiscal year)
Debt = 72.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -671.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.07b USD (5.40b + Debt 72.0m - CCE 1.40b)
Interest Coverage Ratio = -0.57 (Ebit TTM 22.7m / Interest Expense TTM -40.1m)
EV/FCF = 13.08x (Enterprise Value 4.07b / FCF TTM 311.6m)
FCF Yield = 7.65% (FCF TTM 311.6m / Enterprise Value 4.07b)
FCF Margin = 20.06% (FCF TTM 311.6m / Revenue TTM 1.55b)
Net Margin = 14.79% (Net Income TTM 229.7m / Revenue TTM 1.55b)
Gross Margin = 83.16% ((Revenue TTM 1.55b - Cost of Revenue TTM 261.6m) / Revenue TTM)
Gross Margin QoQ = 83.26% (prev 82.20%)
Tobins Q-Ratio = 1.41 (Enterprise Value 4.07b / Total Assets 2.90b)
Interest Expense / Debt = 25.19% (Interest Expense 18.1m / Debt 72.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 18.0m (EBIT 22.7m * (1 - 21.00%))
Current Ratio = 2.54 (Total Current Assets 2.01b / Total Current Liabilities 788.7m)
Debt / Equity = 0.04 (Debt 72.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -25.89 (Net Debt -671.6m / EBITDA 25.9m)
Debt / FCF = -2.16 (Net Debt -671.6m / FCF TTM 311.6m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.26% (Net Income 229.7m / Total Assets 2.90b)
RoE = 12.88% (Net Income TTM 229.7m / Total Stockholder Equity 1.78b)
RoCE = 1.22% (EBIT 22.7m / Capital Employed (Equity 1.78b + L.T.Debt 82.0m))
RoIC = 1.01% (NOPAT 18.0m / Invested Capital 1.78b)
WACC = 11.11% (E(5.40b)/V(5.47b) * Re(10.99%) + D(72.0m)/V(5.47b) * Rd(25.19%) * (1-Tc(0.21)))
Discount Rate = 10.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.99%
[DCF] Terminal Value 66.92% ; FCFF base≈310.4m ; Y1≈300.3m ; Y5≈297.4m
[DCF] Fair Price = 8.61 (EV 3.29b - Net Debt -671.6m = Equity 3.96b / Shares 460.4m; r=11.11% [WACC]; 5y FCF grow -4.47% → 2.90% )
EPS Correlation: 37.81 | EPS CAGR: 42.03% | SUE: -4.0 | # QB: 0
Revenue Correlation: 84.15 | Revenue CAGR: 9.78% | SUE: 2.05 | # QB: 3
EPS next Quarter (2026-04-30): EPS=0.15 | Chg7d=+0.000 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=18
EPS next Year (2027-01-31): EPS=0.76 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+13.4% | Growth Revenue=+9.2%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.8% (Discount Rate 11.0% - Earnings Yield 4.2%)
[Growth] Growth Spread = +3.5% (Analyst 10.3% - Implied 6.8%)
P/E Forward = 16.8919
P/S = 3.4775
P/B = 4.0647
P/EG = 0.4825
Revenue TTM = 1.55b USD
EBIT TTM = 22.7m USD
EBITDA TTM = 25.9m USD
Long Term Debt = 82.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.59m USD (from shortTermDebt, last fiscal year)
Debt = 72.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -671.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.07b USD (5.40b + Debt 72.0m - CCE 1.40b)
Interest Coverage Ratio = -0.57 (Ebit TTM 22.7m / Interest Expense TTM -40.1m)
EV/FCF = 13.08x (Enterprise Value 4.07b / FCF TTM 311.6m)
FCF Yield = 7.65% (FCF TTM 311.6m / Enterprise Value 4.07b)
FCF Margin = 20.06% (FCF TTM 311.6m / Revenue TTM 1.55b)
Net Margin = 14.79% (Net Income TTM 229.7m / Revenue TTM 1.55b)
Gross Margin = 83.16% ((Revenue TTM 1.55b - Cost of Revenue TTM 261.6m) / Revenue TTM)
Gross Margin QoQ = 83.26% (prev 82.20%)
Tobins Q-Ratio = 1.41 (Enterprise Value 4.07b / Total Assets 2.90b)
Interest Expense / Debt = 25.19% (Interest Expense 18.1m / Debt 72.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 18.0m (EBIT 22.7m * (1 - 21.00%))
Current Ratio = 2.54 (Total Current Assets 2.01b / Total Current Liabilities 788.7m)
Debt / Equity = 0.04 (Debt 72.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -25.89 (Net Debt -671.6m / EBITDA 25.9m)
Debt / FCF = -2.16 (Net Debt -671.6m / FCF TTM 311.6m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.26% (Net Income 229.7m / Total Assets 2.90b)
RoE = 12.88% (Net Income TTM 229.7m / Total Stockholder Equity 1.78b)
RoCE = 1.22% (EBIT 22.7m / Capital Employed (Equity 1.78b + L.T.Debt 82.0m))
RoIC = 1.01% (NOPAT 18.0m / Invested Capital 1.78b)
WACC = 11.11% (E(5.40b)/V(5.47b) * Re(10.99%) + D(72.0m)/V(5.47b) * Rd(25.19%) * (1-Tc(0.21)))
Discount Rate = 10.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.99%
[DCF] Terminal Value 66.92% ; FCFF base≈310.4m ; Y1≈300.3m ; Y5≈297.4m
[DCF] Fair Price = 8.61 (EV 3.29b - Net Debt -671.6m = Equity 3.96b / Shares 460.4m; r=11.11% [WACC]; 5y FCF grow -4.47% → 2.90% )
EPS Correlation: 37.81 | EPS CAGR: 42.03% | SUE: -4.0 | # QB: 0
Revenue Correlation: 84.15 | Revenue CAGR: 9.78% | SUE: 2.05 | # QB: 3
EPS next Quarter (2026-04-30): EPS=0.15 | Chg7d=+0.000 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=18
EPS next Year (2027-01-31): EPS=0.76 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+13.4% | Growth Revenue=+9.2%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.8% (Discount Rate 11.0% - Earnings Yield 4.2%)
[Growth] Growth Spread = +3.5% (Analyst 10.3% - Implied 6.8%)